Myomo Q1 revenue $3.8M (+9% YoY); backlog record 275 units; net loss $3.8M

MYOMO, INC.

2024-Q1 EPS reported -$0.10 revenue$3,754,389

Revenue $3.8M (+9% YoY); product revenue $3.75M; revenue units 91 (+14%).
Net loss $3.8M ($0.10/share) vs $2.6M loss a year ago; operating loss $3.9M.
Gross margin 61.2% (down 580bps) on lower ASP, higher warranty reserve and material costs.
Record backlog 275 units (+56%), includes 83 Medicare Part B; orders/authorizations 180 (+48%).
Q2 revenue guidance >$5M; FY2024 guidance $28M-$30M; expects operating cash flow breakeven by Q4 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MYOMO, INC. reported first quarter ended March 31, 2024 results: revenue $3.8 million, net income $3.8 million, or $0.10 per share. Guidance raised.

Period: first quarter ended March 31, 2024
Revenue: $3.8 million
Net income: $3.8 million, or $0.10 per share
Guidance: raised
Result: reported results

Exact text from the filing

Record 275 patients in backlog, includes 180 authorizations and orders in Q1, up 48% over the prior year Record 493 MyoPro candidates added to the pipeline in Q1 Revenue of $3.8 million, up 9% over the prior year Conference call begins at 4:30 p.m. Eastern time today BOSTON (May 8, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable

View on SEC.gov

1447 earnings releases filed in the last 30 days. Browse all earnings releases →

MYOMO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-055687

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.